Quick Answer
Protalix BioTherapeutics, Inc. reported Long Term Debt of $912.0 thousand for the year ending 2014.
- Protalix BioTherapeutics, Inc. showed a decrease of -61.5% in Long Term Debt from 2013 to 2014.
- This data is from Protalix BioTherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2015.
- XBRL data for this metric is available from 2011 to 2014 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $4.45 million | Q3 2011: $4.74 million | Q2 2012: $4.68 million | Q3 2012: $2.79 million | Q1 2013: $2.70 million | Q2 2013: $376.0 thousand | Q4 2014: $912.0 thousand.
- Over the full 4 years of available data (2011 to 2014), Protalix BioTherapeutics, Inc.'s Long Term Debt has declined by 86.1%.
- Historical annual values: Fiscal year 2014: $912.0 thousand | Fiscal year 2013: $2.37 million | Fiscal year 2012: $5.43 million | Fiscal year 2011: $6.57 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: